Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FATE THERAPEUTICS INCFATE · Entity 5968 | Director | June 12, 2026 | June 15, 2026 |
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Chief Financial Officer | September 11, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FATE THERAPEUTICS INC
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.06 · Expires 2036-06-12 | Direct | 87,900 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 87,900 · Balance 87,900 F1: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. F2: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.
F2: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.
NEUROCRINE BIOSCIENCES INC
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,808 |
Ending reported balance
After 2026-09-14 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-11 · Grant · Acquired 5,020 · Balance 47,828 F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. Row 2 · 2026-09-11 · Tax withholding · Disposed 2,709 · Balance 45,119 F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. Row 3 · 2026-09-14 · Sale · Disposed 2,311 · Balance 42,808 F3: The disposition reported on this line was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.05 to $157.43. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
F3: The disposition reported on this line was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F4: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.05 to $157.43. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2024 Filed Feb 15, 2024 22:27 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,352 | $132.85 | $179,611.58 |
DisclosureSEC source: 0000914475-24-000067 · wk-form4_1708036041.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,528 F1 · kind: Sale of 1,352 shares of common stock issued upon vesting of 2,566 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,214) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $133.95. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:12 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 980 | $134.21 | $131,529.23 |
DisclosureSEC source: 0000914475-24-000043 · wk-form4_1707437515.xml · nonDerivative · entry 2 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,314 F3 · kind: Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8 , 2024 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2024 Filed Feb 9, 2024 00:12 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,280 | $142.19 | $182,000.38 |
DisclosureSEC source: 0000914475-24-000043 · wk-form4_1707437515.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,434 F1 · kind: Sale of 1,280 shares of common stock issued upon vesting of 2,430 restricted stock units on February 6 , 2024 to cover payroll and withholding taxes, with the balance of the shares (1,150) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.04 to $143.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,283 | $140.72 | $180,538.76 |
DisclosureSEC source: 0000914475-24-000022 · wk-form4_1706918428.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,284 F1 · kind: Sale of 1,283 shares of common stock issued upon vesting of 2,436 restricted stock units on January 31, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,153) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.67 to $142.10. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 23:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,132 | $107.39 | $228,958.46 |
DisclosureSEC source: 0001209191-23-047127 · doc4.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,131 F1 · kind: Sale of 2,132 shares of common stock issued upon vesting of 4,050 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,918) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.05 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:04 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 10,264 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009879 · doc4.xml · derivative · entry 2 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,264 Underlying: Common Stock · 10,264 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:04 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 63,789 | $0.00 Strike: $103.52 | $0.00 |
DisclosureSEC source: 0001209191-23-009879 · doc4.xml · derivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,789 Underlying: Common Stock · 63,789 shares Expires 2033-02-13 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2023 Filed Feb 9, 2023 00:16 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 980 | $104.19 | $102,110.02 |
DisclosureSEC source: 0001209191-23-007905 · doc4.xml · nonDerivative · entry 5 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,213 F10 · kind: Sale of 980 shares of common stock issued upon vesting of 1,860 restricted stock units on February 8, 2023 to cover payroll and withholding taxes, with the balance of the shares (880) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F11 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.73 to $106.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 00:16 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 11,491 | $102.40 | $1,176,693.34 |
DisclosureSEC source: 0001209191-23-007905 · doc4.xml · nonDerivative · entry 4 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,333 F8 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F9 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $99.93 to $104.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 00:16 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 12,807 | $102.42 | $1,311,687.82 |
DisclosureSEC source: 0001209191-23-007905 · doc4.xml · nonDerivative · entry 3 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,824 F5 · kind: Sale of 12,807 shares of common stock issued upon vesting of 24,298 performance restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (11,491) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on February 7, 2023. F7 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.06 to $103.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 00:16 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,030 | $102.33 | $207,725.43 |
DisclosureSEC source: 0001209191-23-007905 · doc4.xml · nonDerivative · entry 2 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,333 F3 · kind: Sale of 2,030 shares of common stock issued upon vesting of 3,856 restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,826) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.87 to $104.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2023 Filed Feb 9, 2023 00:16 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,280 | $105.67 | $135,253.38 |
DisclosureSEC source: 0001209191-23-007905 · doc4.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,507 F1 · kind: Sale of 1,280 shares of common stock issued upon vesting of 2,430 restricted stock units on February 6, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,150) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.67 to $107.65. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:53 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,283 | $109.98 | $141,107.80 |
DisclosureSEC source: 0001209191-23-006256 · doc4.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,357 F1 · kind: Sale of 1,283 shares of common stock issued upon vesting of 2,436 restricted stock units on January 31, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,153) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2022 Filed Feb 9, 2022 23:51 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 980 | $79.65 | $78,057.59 |
DisclosureSEC source: 0001209191-22-008203 · doc4.xml · nonDerivative · entry 3 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,204 F5 · kind: Sale of 980 shares of common stock issued upon vesting of 1,859 restricted stock units on February 8, 2022 to cover payroll and withholding taxes, with the balance of the shares (879) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.08 to $80.21. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 23:51 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,280 | $80.78 | $103,396.10 |
DisclosureSEC source: 0001209191-22-008203 · doc4.xml · nonDerivative · entry 2 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,325 F3 · kind: Sale of 1,280 shares of common stock issued upon vesting of 2,430 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (1,150) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.79 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 23:51 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,030 | $80.80 | $164,032.12 |
DisclosureSEC source: 0001209191-22-008203 · doc4.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,175 F1 · kind: Sale of 2,030 shares of common stock issued upon vesting of 3,856 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (1,826) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.69 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 00:54 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 9,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006583 · doc4.xml · derivative · entry 2 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,745 Underlying: Common Stock · 9,745 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 00:54 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 66,362 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001209191-22-006583 · doc4.xml · derivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,362 Underlying: Common Stock · 66,362 shares Expires 2032-01-31 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,645 | $82.59 | $135,852.49 |
DisclosureSEC source: 0001209191-21-067870 · doc4.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,349 F1 · kind: Sale of 1,645 shares of common stock issued upon vesting of 3,125 restricted stock units on December 1, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,480) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $80.45 to $85.16. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:30 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 7,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009132 · doc4.xml · derivative · entry 4 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,439 Underlying: Common Stock · 7,439 shares Expires not disclosed F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. F7 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:30 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 44,632 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-009132 · doc4.xml · derivative · entry 3 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,632 Underlying: Common Stock · 44,632 shares Expires 2031-02-08 F5 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:30 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,030 | $116.81 | $237,115.98 |
DisclosureSEC source: 0001209191-21-009132 · doc4.xml · nonDerivative · entry 2 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,869 F3 · kind: Sale of 2,030 shares of common stock issued upon vesting of 3,856 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,826) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $118.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:30 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 880 | $116.85 | $102,825.54 |
DisclosureSEC source: 0001209191-21-009132 · doc4.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,043 F1 · kind: Sale of 880 shares of common stock issued upon vesting of 2,429 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,549) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.9394 to $117.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Mar 27, 2021 01:48 UTC Amendment | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 49,049 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-023367 · doc4a.xml · derivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,049 Underlying: Common Stock · 49,049 shares Expires 2031-02-08 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 21:12 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,645 | $94.66 | $155,720.96 |
DisclosureSEC source: 0001209191-20-061146 · doc4.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,494 F1 · kind: Sale of 1,645 shares of common stock issued upon vesting of 3,125 restricted stock units on December 1, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,480) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $94.17 to $94.95. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 23:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,257 | $90.74 | $204,810.11 |
DisclosureSEC source: 0001209191-20-058532 · doc4.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,014 F1 · kind: Sale of 2,257 shares of common stock issued upon vesting of 4,288 performance restricted stock units to cover withholding taxes, with the balance of the shares (2,031) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $88.93 to $92.23. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:22 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,257 | $118.90 | $268,355.95 |
DisclosureSEC source: 0001209191-20-045716 · doc4.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,983 F1 · kind: Sale of 2,257 shares of common stock issued upon vesting of 4,287 performance restricted stock units to cover withholding taxes, with the balance of the shares (2,030) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $118.29 to $120.71. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 07, 2020 Filed May 12, 2020 00:17 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 15,000 | $73.60 Strike: $73.60 | $1,104,000.00 |
DisclosureSEC source: 0001209191-20-028394 · doc4.xml · derivative · entry 3 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 15,000 shares Expires 2027-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted December 1, 2017 and vested at 25% upon first anniversary (December 1, 2018) and remaining 75% vesting in 36 equal monthly installments beginning November 1, 2018. Read SEC document |
| May 07, 2020 Filed May 12, 2020 00:17 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 15,000 | $110.21 | $1,653,133.50 |
DisclosureSEC source: 0001209191-20-028394 · doc4.xml · nonDerivative · entry 2 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,953 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.95. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 07, 2020 Filed May 12, 2020 00:17 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 15,000 | $73.60 | $1,104,000.00 |
DisclosureSEC source: 0001209191-20-028394 · doc4.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 20:25 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,741 | $102.49 | $178,435.09 |
DisclosureSEC source: 0001209191-20-026302 · doc4.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,953 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| April 24, 2020 Filed Apr 29, 2020 00:32 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,934 | $99.52 | $192,466.85 |
DisclosureSEC source: 0001209191-20-026062 · doc4.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,694 F1 · kind: Sale of 1,934 shares of common stock issued upon vesting of 3,675 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (1,741) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.56 to $101.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes 252 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 28, 2020. Read SEC document |
| February 07, 2020 Filed Feb 12, 2020 00:06 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,030 | $103.35 | $209,806.59 |
DisclosureSEC source: 0001209191-20-008478 · doc4.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,701 F1 · kind: Sale of 2,030 shares of common stock issued upon vesting of 3,855 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,825) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.24 to $104.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:40 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 9,719 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007678 · doc4.xml · derivative · entry 2 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,719 Underlying: Common Stock · 9,719 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:40 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 61,347 | $0.00 Strike: $102.90 | $0.00 |
DisclosureSEC source: 0001209191-20-007678 · doc4.xml · derivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,347 Underlying: Common Stock · 61,347 shares Expires 2030-02-06 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 23:06 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,645 | $116.33 | $191,360.38 |
DisclosureSEC source: 0001209191-19-059146 · doc4.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,876 F1 · kind: Sale of 1,645 shares of common stock issued upon vesting of 3,125 restricted stock units on December 2, 2019 to cover payroll and withholding taxes, with the balance of the shares (1,480) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $114.92 to $117.72. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes a total of 449 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan. 329 shares on February 28, 2019 and 120 shares on August 30, 2019. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 22:04 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 15,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008625 · doc4.xml · derivative · entry 2 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,423 Underlying: Common Stock · 15,423 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 22:04 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 83,341 | $0.00 Strike: $81.05 | $0.00 |
DisclosureSEC source: 0001209191-19-008625 · doc4.xml · derivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,341 Underlying: Common Stock · 83,341 shares Expires 2029-02-07 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 7, 2019 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 22:54 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,178 | $90.00 | $106,019.65 |
DisclosureSEC source: 0001209191-18-061372 · doc4.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,947 F1 · kind: Sale of 1,178 shares of common stock issued upon vesting of 3,125 restricted stock units on December 3, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,947) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $89.8493 to $90.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 22:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 12,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008205 · doc4.xml · derivative · entry 2 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2020-02-05 F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F3 · derivative.exercise_date: Performance Restricted Stock Units ("PRSU") will vest upon the date the Company has achieved both (1) obtaining positive pivotal clinical trial data for the treatment of Tourette syndrome with valbenazine and (2) FDA acceptance of a New Drug Application for the treatment of Tourette syndrome with valbenazine. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 22:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 12,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008205 · doc4.xml · derivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2021-03-15 F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F2 · derivative.exercise_date: A portion of this grant will vest upon FDA approval of opicapone within a specified time period, and portions of this grant will vest upon achievement of specified revenue milestones within a specified time period. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:24 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-063918 · doc4.xml · derivative · entry 2 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 25% of the units vesting on each of December 1, 2018, December 1, 2019, December 1, 2020, and December 1, 2021. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 25% of the units vesting on each of December 1, 2018, December 1, 2019, December 1, 2020, and December 1, 2021. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:24 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 60,000 | $0.00 Strike: $73.60 | $0.00 |
DisclosureSEC source: 0001209191-17-063918 · doc4.xml · derivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-12-01 F1 · derivative.exercise_date: Represents option of which 1/4th of the shares underlying the option becomes vested and exercisable on December 1, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.